- By insider
CEO of Arrowhead Pharmaceuticals Inc (30-Year Financial, Insider Trades) Christopher Richard Anzalone (insider trades) sold 100,000 shares of ARWR on 10/23/2020 at an average price of $58.21 a share. The total sale was $5.8 million.
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins. Arrowhead Pharmaceuticals Inc has a market cap of $6.02 billion; its shares were traded at around $58.88 with and P/S ratio of 47.77. GuruFocus has detected 2 severe warning signs with Arrowhead Pharmaceuticals Inc. .
CEO Recent Trades:
-
CEO Christopher Richard Anzalone sold 100,000 shares of ARWR stock on 10/23/2020 at the average price of $58.21. The price of the stock has increased by 1.15% since.
CFO Recent Trades:
-
CFO Kenneth Allen Myszkowski sold 29,166 shares of ARWR stock on 10/20/2020 at the average price of $54.04. The price of the stock has increased by 8.96% since.
Directors and Officers Recent Trades:
-
Director Mauro Ferrari sold 10,000 shares of ARWR stock on 10/09/2020 at the average price of $48. The price of the stock has increased by 22.67% since.
For the complete insider trading history of ARWR, click here
.This article first appeared on GuruFocus.